Drug Trial Radar · NCT04546009
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
992
Actual
Start
Oct 9, 2020
Primary completion
Jan 30, 2026
Study completion Jul 28, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.
Conditions
- Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Interventions
GiredestrantDrug
Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
Giredestrant-matched PlaceboDrug
Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
LetrozoleDrug
Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
Letrozole-matched PlaceboDrug
Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
PalbociclibDrug
Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.
LHRH AgonistDrug
Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)
Locations
256 sites in 30 countries. Site status is shown where the registry gives one.
Orange Coast Memorial Medical Center
Fountain Valley, California
Long Beach Memorial Medical Center
Long Beach, California
Kaiser Permanente - San Leandro Medical Center
San Leandro, California
Stanford Univ Medical Center
Stanford, California
Kaiser Permanente - Walnut Creek
Walnut Creek, California
University of Colorado
Aurora, Colorado
Rocky Mountain Cancer Center
Denver, Colorado
Florida Cancer Specialists - Fort Myers (Broadway)
Fort Myers, Florida
Memorial Regional Cancer Ctr
Hollywood, Florida
University of Miami
Miami, Florida
SCRI Florida Cancer Specialists North
St. Petersburg, Florida
SCRI Florida Cancer Specialists PAN
Tallahassee, Florida
Kaiser Permanente - Moanalua Medical Center
Honolulu, Hawaii
Mercy Medical Center
Baltimore, Maryland
Maryland Oncology Hematology
Silver Spring, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
HCA Midwest Division
Kansas City, Missouri
Memorial Sloan Kettering Cancer Center Basking Ridge
Basking Ridge, New Jersey
Astera Cancer Care East Brunswick
East Brunswick, New Jersey
Memorial Sloan Kettering Cancer Center at Bergen
Montvale, New Jersey
San Juan Oncology Associates
Farmington, New Mexico
MSKCC @ Commack
Commack, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
The Cleveland Clinic Foundation
Cleveland, Ohio
Providence Portland Medical Ctr
Portland, Oregon
Roper St. Francis Healthcare
Charleston, South Carolina
West Cancer Center
Germantown, Tennessee
Sarah Cannon Research Institute / Tennessee Oncology
Nashville, Tennessee
Texas Oncology - DFW
Dallas, Texas
The Center for Cancer and Blood Disorders - Fort Worth
Fort Worth, Texas
Baylor St. Luke's Medical Center
Houston, Texas
Houston Methodist Hospital
Houston, Texas
Inova Fairfax Hospital
Fairfax, Virginia
Virginia Oncology Associates
Norfolk, Virginia
Northwest Medical Specialties
Tacoma, Washington
University of Wisconsin
Madison, Wisconsin
Hospital de Onc Angel Roffo
Buenos Aires, Argentina
Organización medica de Investi
Cap Fed, Argentina
Showing 40 of 256 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.